These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

892 related items for PubMed ID: 26792812

  • 1. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
    Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, Stevens RM, Vessey A, Zhan X, Bird P.
    Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812
    [Abstract] [Full Text] [Related]

  • 2. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
    Cutolo M, Myerson GE, Fleischmann RM, Lioté F, Díaz-González F, Van den Bosch F, Marzo-Ortega H, Feist E, Shah K, Hu C, Stevens RM, Poder A.
    J Rheumatol; 2016 Sep; 43(9):1724-34. PubMed ID: 27422893
    [Abstract] [Full Text] [Related]

  • 3. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
    Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Lespessailles E, Hall S, Hochfeld M, Hu C, Hough D, Stevens RM, Schett G.
    Ann Rheum Dis; 2014 Jun; 73(6):1020-6. PubMed ID: 24595547
    [Abstract] [Full Text] [Related]

  • 4. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
    Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Hochfeld M, Teng LL, Schett G, Lespessailles E, Hall S.
    J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
    [Abstract] [Full Text] [Related]

  • 5. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).
    Nash P, Ohson K, Walsh J, Delev N, Nguyen D, Teng L, Gómez-Reino JJ, Aelion JA, ACTIVE investigators.
    Ann Rheum Dis; 2018 May; 77(5):690-698. PubMed ID: 29343507
    [Abstract] [Full Text] [Related]

  • 6. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM.
    Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
    [Abstract] [Full Text] [Related]

  • 7. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.
    Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N, Teng L, Paris M, Mease PJ.
    Arthritis Res Ther; 2019 May 10; 21(1):118. PubMed ID: 31077258
    [Abstract] [Full Text] [Related]

  • 8. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
    Rich P, Gooderham M, Bachelez H, Goncalves J, Day RM, Chen R, Crowley J.
    J Am Acad Dermatol; 2016 Jan 10; 74(1):134-42. PubMed ID: 26549249
    [Abstract] [Full Text] [Related]

  • 9. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Deeks ED.
    Drugs; 2015 Aug 10; 75(12):1393-403. PubMed ID: 26220911
    [Abstract] [Full Text] [Related]

  • 10. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.
    Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey AR, Hu C, Stevens R, de Vlam KL.
    Arthritis Rheum; 2012 Oct 10; 64(10):3156-67. PubMed ID: 22806399
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
    Stein Gold L, Bagel J, Lebwohl M, Jackson JM, Chen R, Goncalves J, Levi E, Duffin KC.
    J Drugs Dermatol; 2018 Feb 01; 17(2):221-228. PubMed ID: 29462231
    [Abstract] [Full Text] [Related]

  • 12. Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients.
    Wells AF, Edwards CJ, Kivitz AJ, Bird P, Guerette B, Delev N, Paris M, Teng L, Aelion JA.
    Rheumatology (Oxford); 2022 Mar 02; 61(3):1035-1043. PubMed ID: 34100922
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
    Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb AB.
    Br J Dermatol; 2015 Dec 02; 173(6):1387-99. PubMed ID: 26357944
    [Abstract] [Full Text] [Related]

  • 14. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
    Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, Day RM, Goncalves J, Shah K, Piguet V, Soung J.
    J Eur Acad Dermatol Venereol; 2017 Mar 02; 31(3):507-517. PubMed ID: 27768242
    [Abstract] [Full Text] [Related]

  • 15. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1).
    Schafer PH, Chen P, Fang L, Wang A, Chopra R.
    J Immunol Res; 2015 Mar 02; 2015():906349. PubMed ID: 25973439
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
    Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, Hu C, Day RM.
    Lancet; 2012 Aug 25; 380(9843):738-46. PubMed ID: 22748702
    [Abstract] [Full Text] [Related]

  • 17. Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study.
    Genovese MC, Jarosova K, Cieślak D, Alper J, Kivitz A, Hough DR, Maes P, Pineda L, Chen M, Zaidi F.
    Arthritis Rheumatol; 2015 Jul 25; 67(7):1703-10. PubMed ID: 25779750
    [Abstract] [Full Text] [Related]

  • 18. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
    Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, Hu C, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CE.
    J Am Acad Dermatol; 2015 Jul 25; 73(1):37-49. PubMed ID: 26089047
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
    Reich K, Gooderham M, Bewley A, Green L, Soung J, Petric R, Marcsisin J, Cirulli J, Chen R, Piguet V.
    J Eur Acad Dermatol Venereol; 2018 Mar 25; 32(3):397-402. PubMed ID: 29220542
    [Abstract] [Full Text] [Related]

  • 20. Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis.
    Haber SL, Hamilton S, Bank M, Leong SY, Pierce E.
    Ann Pharmacother; 2016 Apr 25; 50(4):282-90. PubMed ID: 26783350
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.